American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
2.
BahaliK, UneriOS, IpekH: Atomoxetine-induced mania-like symptoms in an adolescent patient. Actas Esp Psiquiatr, 41:137–138, 2013.
3.
BhanjiNH, MargoleseHC, Saint–LaurentM, ChouinardG: Dysphoric mania induced by high-dose mirtazapine: A case for ‘norepinephrine syndrome’?. Int Clin Psychopharmacol, 17:319–322, 2002.
4.
BlochMH, PanzaKE, Landeros–WeisenbergerA, LeckmanJF: Meta-analysis: Treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J AmAcad Child Adolesc Psychiatry, 48:884–893, 2009.
5.
ChristmanAK, FermoJD, MarkowitzJS: Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy, 24:1020–1036, 2004.
6.
DalsgaardS, MortensenPB, FrydenbergM, MaibingCM, NordentoftM, ThomsenPH: Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry, 29:259–263, 2014.
7.
DaltegA, ZandelinA, TuningerE, LevanderS: Psychosis in adulthood is associated with high rates of ADHD and CD problems during childhood. Nord J Psychiatry, 2014 [Epub ahead of print].
8.
GauSS, NiHC, ShangCY, SoongWT, WuYY, LinLY, ChiuYN: Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Aust N Z J Psychiatry. 44:135–143, 2010.
9.
GuneyE, UneriOS: Atomoxetine-induced hypomania-like symptoms in a preadolescent patient. J Child Adolesc Psychopharmacol, 2014 [Epub ahead of print].
LarssonH, RydenE, BomanM, LangstromN, LichtensteinP, LandenM: Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry, 203:103–106, 2013.
12.
MoronJA, BrockingtonA, WiseRA, RochaBA, HopeBT: Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J Neurosci, 22:389–395, 2002.
13.
PringsheimT, SteevesT.: Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev, 4:CD007990, 2011.
14.
SteinbergS, ChouinardG: A case of mania associated with tomoxetine. Am J Psychiatry, 142:1517–1518, 1985.
15.
SwansonCJ, PerryKW, Koch–KruegerS, KatnerJ, SvenssonKA, BymasterFP: Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology, 50:755–760, 2006.
16.
TangCS, ChouWJ, ChengAT: Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation. J Child Adolesc Psychopharmacol, 19:319–320, 2009.
17.
WillcuttEG: The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics, 9:490–499, 2012.
